Navigation Links
Behavioral therapy in pediatric antidepressant treatment reduces likelihood of relapse
Date:7/2/2014

DALLAS July 2, 2014 Cognitive behavioral therapy in addition to medication improves the long-term success of treatment for children and adolescents suffering from depression, a new UTSouthwestern Medical Center study indicates.

Based on the results of a clinical trial conducted at UTSouthwestern and Children's Medical Center of Dallas, depression relapse rates were substantially lower in a group of youth who received both forms of treatment versus medication alone.

"Continuation-phase strategies designed to reduce the high rates of relapse in depressed youths have important public health implications, as recurrence of depression is more likely in youths with multiple episodes," said Dr. Betsy Kennard, Professor of Psychiatry at UTSouthwestern and senior author of the study published June 17 in The American Journal of Psychiatry.

Relapse rates in youth with major depressive disorders typically range from 40 percent to 70 percent, said Dr. Kennard, also Director of an outpatient program at Children's Medical Center called Suicide Prevention and Resilience at Children's (SPARC).

In this study, the relapse rate for the group of 75 youth who received behavioral therapy for six months following six weeks of initial treatment with the antidepressant fluoxetine, also known as Prozac, was 9 percent. Among the group of 69 youth who received only the drug during this period, 26.5 percent relapsed.

Youth who showed improvement after receiving fluoxetine for an initial six-week treatment period continued in the study, split between the medication-only and therapy plus medication groups. Study participants' ages ranged from 8-17.

"Unfortunately, medication alone is not always enough to prevent relapse," said Dr. Graham Emslie, Chief of the Division of Adolescent and Child Psychiatry, Professor of Psychiatry and Pediatrics at UTSouthwestern, and a contributing author of the study. "Identifying novel strategies to prevent future relapses for young people should be a priority. This approach is unique in that treatment was added at a time when the intensity of care is frequently decreasing."

The type of therapy used in this trial called Relapse Prevention Cognitive Behavioral Therapy is an individual psychotherapy treatment with a family component that focuses on reducing residual symptoms, increasing wellness behaviors, and preventing relapse. For six months, the youth in this arm of the trial participated in eight to 11 therapy sessions that were tailored to each child.

"It is also worth noting that youth who received the therapy had lower medication doses, yet had better outcomes than those on higher dosages in the medication management-only group," said Dr. Kennard.


'/>"/>

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Lead in kids blood linked with behavioral and emotional problems
2. NYU researchers pilot educational and behavioral program to reduce lymphedema risk
3. Cognitive behavioral or relaxation training helps women reduce distress during breast cancer treatment
4. IADR and Unilever partner to launch new behavioral research award
5. New project on psychiatric, neurologic, and behavioral genetics
6. Adding cognitive behavioral therapy to treatment of pediatric migraine improves relief of symptoms
7. Susquehanna Health Behavioral Health Professional Addresses Mental Health Parity
8. Mississippi Department of Mental Health Selects CoCENTRIX for EHR and to Coordinate Care for Its Citizens Treated in State Behavioral Health and I/DD Programs
9. Experts Examine the Success of Cognitive Behavioral Therapy in Treating Depression Among Older Veterans
10. The 54th National Dialogues on Behavioral Health Conference Prepares Behavioral Health Organizations for Evolving Markets on Eve of ACA Implementation
11. Study suggests antioxidant treatment may help NF1-linked behavioral issues
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Behavioral therapy in pediatric antidepressant treatment reduces likelihood of relapse
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is ... from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... body recognizes its raw form (unlike the synthetically made options that are on the ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... performance, is proud to announce that it has received 510(k) clearance from the ... MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling systems ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
Breaking Medicine Technology: